Thymic carcinoma other diagnostic studies

Thymic Carcinoma Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Thymic carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiograph and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Thymic carcinoma other diagnostic studies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Google Images
American Roentgen Ray Society Images of Thymic carcinoma other diagnostic studies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Thymic carcinoma other diagnostic studies
CDC on Thymic carcinoma other diagnostic studies
Thymic carcinoma other diagnostic studies in the news
Blogs on Thymic carcinoma other diagnostic studies
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Thymic carcinoma other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]

Other Diagnostic Studies

Immunohistochemistry

For the subtype squamous cell carcinomas, the epithelial cells are immunoreactive to CD5, CD70 and CD117. In contrast with thymomas that are negative to CD5. For squamous cell carcinomas of other locations, the CD5 and CD70 are negative, meaning that this is useful to confirm the thymic origin of the tumor.